High baseline Tie1 level predicts poor survival in metastatic breast cancer.
Adult
Aged
Angiopoietin-2
/ blood
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bevacizumab
/ administration & dosage
Biomarkers, Tumor
/ blood
Breast
/ pathology
Breast Neoplasms
/ blood
Docetaxel
/ administration & dosage
Drug Administration Schedule
Female
Humans
Middle Aged
Prognosis
Progression-Free Survival
Prospective Studies
Receptor, TIE-1
/ metabolism
Survival Analysis
Angiogenesis
Angiopoietin-2
Metastatic breast cancer
Prognostic marker
Tie1
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
24 Jul 2019
24 Jul 2019
Historique:
received:
20
09
2018
accepted:
19
07
2019
entrez:
26
7
2019
pubmed:
26
7
2019
medline:
15
2
2020
Statut:
epublish
Résumé
Angiopoietin growth factors (Angs) regulate angiogenesis and lymphangiogenesis by binding to the endothelial Tie2 receptor. Ang2 expression is elevated in tissue hypoxia and inflammation, which also induce cleavage of the extracellular domain of the orphan Tie1 receptor. Here we have examined if the concentrations of Ang2 and the soluble extracellular domain of Tie1 in patient plasma are associated with the prognosis of patients with metastatic breast cancer. Plasma Tie1 and Ang2 levels were measured in metastatic breast cancer patients treated in a phase II trial with a taxane-bevacizumab combination chemotherapy in the first-line treatment setting. They were analyzed before treatment, after 6 weeks and 6 months of treatment, and at the final study visit. Using the median concentrations as cutoffs, Tie1 and Ang2 data were dichotomized into low and high concentration groups. Additionally, we analyzed Tie1 concentrations in plasma from 10 healthy women participating in a breast cancer primary prevention study. Plasma samples were available from 58 (89%) of the 65 patients treated in the trial. The baseline Tie1 levels of the healthy controls were significantly lower than those of the metastatic patients (p < 0.001). The overall survival of the patients with a high baseline Tie1 level was significantly shorter (multivariate HR 3.07, 95% CI 1.39-6.79, p = 0.005). Additionally, the progression-free survival was shorter for patients with a high baseline Tie1 level (multivariate HR 3.78, 95% CI 1.57-9.09, p = 0.003). In contrast, the baseline Ang2 levels had no prognostic impact in a multivariate Cox proportional hazard regression analysis. The combined analysis of baseline Tie1 and Ang2 levels revealed that patients with both high Tie1 and high Ang2 baseline levels had a significantly shorter overall survival than the patients with low baseline levels of both markers (multivariate HR for overall survival 4.32, 95% CI 1.44-12.94, p = 0.009). This is the first study to demonstrate the prognostic value of baseline Tie1 plasma concentration in patients with metastatic breast cancer. Combined with the results of the Ang2 analyses, the patients with both high Tie1 and Ang2 levels before treatment had the poorest survival. Clinicaltrials.gov: NCT00979641, registration date 19-DEC-2008. The regional Ethics Committee: R08142M, registration date 18-NOV-2008.
Sections du résumé
BACKGROUND
BACKGROUND
Angiopoietin growth factors (Angs) regulate angiogenesis and lymphangiogenesis by binding to the endothelial Tie2 receptor. Ang2 expression is elevated in tissue hypoxia and inflammation, which also induce cleavage of the extracellular domain of the orphan Tie1 receptor. Here we have examined if the concentrations of Ang2 and the soluble extracellular domain of Tie1 in patient plasma are associated with the prognosis of patients with metastatic breast cancer.
METHODS
METHODS
Plasma Tie1 and Ang2 levels were measured in metastatic breast cancer patients treated in a phase II trial with a taxane-bevacizumab combination chemotherapy in the first-line treatment setting. They were analyzed before treatment, after 6 weeks and 6 months of treatment, and at the final study visit. Using the median concentrations as cutoffs, Tie1 and Ang2 data were dichotomized into low and high concentration groups. Additionally, we analyzed Tie1 concentrations in plasma from 10 healthy women participating in a breast cancer primary prevention study.
RESULTS
RESULTS
Plasma samples were available from 58 (89%) of the 65 patients treated in the trial. The baseline Tie1 levels of the healthy controls were significantly lower than those of the metastatic patients (p < 0.001). The overall survival of the patients with a high baseline Tie1 level was significantly shorter (multivariate HR 3.07, 95% CI 1.39-6.79, p = 0.005). Additionally, the progression-free survival was shorter for patients with a high baseline Tie1 level (multivariate HR 3.78, 95% CI 1.57-9.09, p = 0.003). In contrast, the baseline Ang2 levels had no prognostic impact in a multivariate Cox proportional hazard regression analysis. The combined analysis of baseline Tie1 and Ang2 levels revealed that patients with both high Tie1 and high Ang2 baseline levels had a significantly shorter overall survival than the patients with low baseline levels of both markers (multivariate HR for overall survival 4.32, 95% CI 1.44-12.94, p = 0.009).
CONCLUSIONS
CONCLUSIONS
This is the first study to demonstrate the prognostic value of baseline Tie1 plasma concentration in patients with metastatic breast cancer. Combined with the results of the Ang2 analyses, the patients with both high Tie1 and Ang2 levels before treatment had the poorest survival.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov: NCT00979641, registration date 19-DEC-2008. The regional Ethics Committee: R08142M, registration date 18-NOV-2008.
Identifiants
pubmed: 31340773
doi: 10.1186/s12885-019-5959-8
pii: 10.1186/s12885-019-5959-8
pmc: PMC6657075
doi:
Substances chimiques
ANGPT2 protein, human
0
Angiopoietin-2
0
Biomarkers, Tumor
0
Docetaxel
15H5577CQD
Bevacizumab
2S9ZZM9Q9V
Receptor, TIE-1
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT00979641']
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
732Références
Clin Cancer Res. 1999 Jul;5(7):1745-51
pubmed: 10430078
Anticancer Res. 2001 May-Jun;21(3C):2163-70
pubmed: 11501841
Int J Cancer. 2003 Feb 10;103(4):466-74
pubmed: 12478661
Tumour Biol. 2003 Mar-Apr;24(2):61-9
pubmed: 12853700
J Cell Biol. 2005 Apr 25;169(2):239-43
pubmed: 15851516
Clin Cancer Res. 2009 Feb 15;15(4):1384-92
pubmed: 19228739
Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77
pubmed: 19234476
Br J Cancer. 2010 Oct 26;103(9):1407-14
pubmed: 20924372
Cancer Cell. 2011 Apr 12;19(4):512-26
pubmed: 21481792
Histopathology. 2011 Aug;59(2):256-63
pubmed: 21884204
J Clin Oncol. 2012 Feb 1;30(4):441-4
pubmed: 22184396
Crit Care Med. 2012 Nov;40(11):3034-41
pubmed: 22890252
Exp Cell Res. 2013 May 15;319(9):1271-80
pubmed: 23500414
Ann Oncol. 2013 Nov;24(11):2773-80
pubmed: 23894038
J Clin Invest. 2014 Feb;124(2):824-34
pubmed: 24430181
Transl Oncol. 2014 Apr;7(2):188-95
pubmed: 24704536
Cell Rep. 2014 Aug 7;8(3):696-706
pubmed: 25088418
Breast. 2015 Jun;24(3):182-90
pubmed: 25747197
Int J Clin Exp Pathol. 2015 Jan 01;8(1):660-4
pubmed: 25755760
Nat Rev Drug Discov. 2016 Jun;15(6):385-403
pubmed: 26775688
Clin Cancer Res. 2016 Apr 1;22(7):1611-20
pubmed: 26823602
Br J Cancer. 2016 Apr 12;114(8):855-62
pubmed: 27031850
Gynecol Oncol. 2016 Oct;143(1):27-34
pubmed: 27546885
J Clin Invest. 2016 Sep 1;126(9):3511-25
pubmed: 27548529
J Clin Invest. 2016 Sep 1;126(9):3495-510
pubmed: 27548530
Anticancer Res. 2016 Dec;36(12):6431-6438
pubmed: 27919965
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381
pubmed: 28396439
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404865
Cancer Med. 2017 Jun;6(6):1378-1388
pubmed: 28464467
Nat Rev Drug Discov. 2017 Sep;16(9):635-661
pubmed: 28529319
J Clin Invest. 2018 Feb 1;128(2):834-845
pubmed: 29355844
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Clin Breast Cancer. 2019 Aug;19(4):e522-e533
pubmed: 31029558
Cancer Res. 1994 Dec 15;54(24):6571-7
pubmed: 7987857
Science. 1997 Jul 4;277(5322):55-60
pubmed: 9204896